ライフサイエンスコーパス: amputation

1 claudication, leg revascularisation, and leg amputation).

2 incidence of in-hospital mortality and major amputation.

3 somatosensory cortex even decades after arm amputation.

4 diabetes and frequently leads to major limb amputation.

5 ema during epimorphic fin regeneration after amputation.

6 the territory of the missing hand following amputation.

7 r or surgical intervention, and 5% underwent amputation.

8 reconstructive surgery owing to a traumatic amputation.

9 scularizable limb ischemia can prevent major amputation.

10 ion, improves tissue perfusion, and prevents amputation.

11 dovascular interventions, in the year before amputation.

12 f the infected tissue, and, in severe cases, amputation.

13 e use of arterial testing in patients before amputation.

14 rates of peripheral arterial disease-related amputation.

15 oung adult rats (n=5) at 7 to 24 weeks after amputation.

16 ng between 0 to 12 and 0 to 24 months before amputation.

17 imited capacity to regenerate bone after fin amputation.

18 event rates in terms of total mortality and amputation.

19 ortical reorganization that follows forelimb amputation.

20 ial ulcers and high rates of MACCE and major amputation.

21 atosensory cortex (SI) that follows forelimb amputation.

22 e, or both; 36% were admitted only for their amputation.

23 arian flatworms regenerate every organ after amputation.

24 arkable ability to regenerate its limb after amputation.

25 +/-0.65 months in non-African Americans with amputation.

26 arly two regenerations of flagella following amputation.

27 n-cluster zones over the first 12 weeks post-amputation.

28 with time after transplantation and level of amputation.

29 urrent infections, tissue necrosis, and limb amputation.

30 the deafferented territory immediately after amputation.

31 54.9+/-1.06 months in African Americans with amputation.

32 nd higher risk of below-knee lower extremity amputation.

33 nal transplant recipients, 1062 patients had amputation.

34 a major complication after severe trauma or amputation.

35 a strong association between albuminuria and amputation.

36 ality among groups, and no patient underwent amputation.

37 ocedure, wound progression, or subsequent to amputation.

38 ety end point was below-knee lower extremity amputation.

39 s can re-grow many parts of their body after amputation.

40 The primary outcome was major amputation.

41 as major adverse limb events including major amputation.

42 stroke rates, and increased risk of ischemic amputation.

43 cally de-efferented and de-afferented due to amputation.

44 capillary density, motor function, and their amputation.

45 often associated with risk of infection and amputation.

46 d with high risk of infection and lower-limb amputation.

47 s 5 mg/g was 3.68 (95% CI 3.00-4.52) for leg amputation.

48 as infected foot ulcers, which often lead to amputation.

49 onditions and after exfoliation or appendage amputation.

50 blindness, chronic kidney disease, and limb amputation.

51 ce- or procedure-related deaths and no major amputations.

52 and 3 years, and no difference in subsequent amputations.

53 n and are at risk of falls, ulcerations, and amputations.

54 knee (n = 6) or knee-disarticulation (n = 1) amputations.

55 eplicas of the originals even after repeated amputations.

56 and 1 patient required lower limb and finger amputations.

57 tions are a leading cause of lower extremity amputations.

58 inability to work, physical deformities, and amputations.

59 imited treatment options, often resulting in amputations.

60 ld higher risk of below-knee lower extremity amputation (0.17 versus 0.09 events per 100 person-years

61 4.1% vs. 1.1%, respectively; p = 0.003), and amputation (10.1% vs. 2.4%, respectively; p < 0.001) dur

62 larization, 18.2% (95% CI, 14.5-22.6); major amputation, 14.9% (95% CI, 12.3-18.0); and all-cause mor

63 atients with amputation versus those without amputation (19.9% vs. 7.3%; P=0.0001).

64 atosensory cortex after brain damage [1] and amputation [2].

65 e hearing loss (5.4%), skin scarring (5.4%), amputation (3.4%), renal dysfunction (2.6%), and seizure

66 nd major adverse limb events including major amputation (32 [1%] vs 60 [2%]; HR 0.54 95% CI 0.35-0.82

67 rterial revascularization or lower extremity amputation, 4.6% died, and the median cost of a readmiss

68 ed major adverse limb events including major amputation (40 [2%] vs 60 [2%]; HR 0.67, 95% CI 0.45-1.0

69 anagliflozin except for an increased risk of amputation (6.3 vs. 3.4 participants per 1000 patient-ye

70 5, p < 0.001) despite similar rates of major amputation (6.5% vs. 5.7%, p = 0.75).

71 cation of amputation and was lowest for foot amputation (62.5%), followed by above-knee amputation (6

72 Among patients who ultimately underwent an amputation, 64% were admitted to the hospital in the yea

73 mong 17 463 patients undergoing nontraumatic amputation, 68.4% underwent some type of arterial testin

74 t amputation (62.5%), followed by above-knee amputation (69.0%) and below-knee amputation (76.7%; P<0

75 above-knee amputation (69.0%) and below-knee amputation (76.7%; P<0.001).

76 ular care in the year before lower extremity amputation, across hospital referral regions.

77 adjusted HR, 0.47; 95% CI, 0.29-0.77), minor amputation (adjusted HR, 0.26; 95% CI, 0.13-0.54), bypas

78 VR group were also less likely to have major amputation (adjusted HR, 0.47; 95% CI, 0.29-0.77), minor

79 CLI patients and positively correlated with amputation after restenosis at 12 months postrevasculari

80 rovide better 6-month patency rates and less amputations after 6 and 12 months compared with PTA+/-BM

81 ary patency, repeat revascularization, major amputation, all-cause mortality) outcomes.

82 rtality or risk of cardiovascular events and amputation among patients with peripheral arterial disea

83 n the United Kingdom found that 25% required amputation and 20% (including some subjects who had requ

84 novel patterns of referred sensations after amputation and attributable to cortical plasticity.

85 case we proposed an uncommon evolution: auto-amputation and calcification of an esophageal mesenchyma

86 30 days, and freedom from target limb major amputation and clinically driven target lesion revascula

87 procedure and freedom from target limb major amputation and clinically driven target lesion revascula

88 with diabetes who were undergoing major limb amputation and control subjects.

89 s well as psychosocial, consequences such as amputation and depression.

90 showed decreasing use of surgical bypass and amputation and increasing rates of catheter-based thromb

91 The prevalence of renal posttransplantation amputation and its impact on allograft and patient survi

92 bone tumor characterized with a high risk of amputation and malignant morbidity among teenagers and a

93 Rates of amputation and revascularization for peripheral vascular

94 testing varied significantly by location of amputation and was lowest for foot amputation (62.5%), f

95 on in an 8-year-old child with quadrimembral amputations and a previous kidney transplant.

96 ction of hospitalization time, prevention of amputations and better understanding of the processes wh

97 are few therapeutic alternatives, leading to amputations and death.

98 Amputations and recurrences in patients with eumycetoma

99 r surgical therapy (revascularization and/or amputation) and were discharged alive were identified in

100 s the cornerstone of therapy to prevent limb amputation, and both open vascular surgery and endovascu

101 ulder first appears in the FBS 4 weeks after amputation, and by 6 weeks, the new shoulder input comes

102 as a composite of all-cause mortality, major amputation, and CD-TLR.

103 Stenosis >50%, retreatment, major amputation, and critical limb ischemia-related death wer

104 cal limb ischemia (CLI), foot ulcers, former amputation, and impaired regeneration are independent ri

105 m a medical complication related to a limb), amputation, and reintervention.

106 m from a composite of all death, target limb amputation, and target lesion revascularization at 30 da

107 myocardial infarction, transfusion, stroke, amputation, and the composite end points of major advers

108 utaneous wounds, leading to hospitalization, amputations, and death.

109 reductions in myocardial infarction, stroke, amputations, and mortality.

110 Minor amputations are often required for tissue loss as a part

111 Over 60% of lower extremity amputations are performed in patients with diabetes and

112 nt interaction between travel time and major amputation as well as travel time and revascularization

113 Here, the authors use an amputation assay in Xenopus laevis to demonstrate that r

114 Here we use an amputation assay in Xenopus laevis to show that absence

115 observed for the primary outcome, ie, major amputation at 6 months, with major amputation rates of 1

116 t of injury with either (1) a traumatic limb amputation at or above the knee or elbow or (2) shock de

117 Major amputations (at or above the ankle) limit functional ind

118 ive option for patients who have experienced amputation because of trauma.

119 n revascularization, thrombosis, ipsilateral amputation, binary restenosis, and all-cause mortality a

120 ecently, a long jumper with a below the knee amputation (BKA) achieved jump distances similar to worl

121 is not restricted to fin regeneration after amputation, but also occurs during repair of zebrafish f

122 does not remain 'silent' after bilateral arm amputation, but rather is recruited by other modalities

123 showed that cell therapy reduced the risk of amputation by 37%, improved amputation-free survival by

124 ondary outcomes included rates of lower limb amputations, bypass surgical procedures, and peripheral

125 age, female sex, black/Hispanic race, prior amputation, Charlson comorbidity index, and need for hom

126 vascular patients had died or received major amputation compared with 54% of open patients (P < 0.001

127 vascular patients had died or received major amputation compared with 54% of open patients (P < 0.001

128 to have 1.77 times the odds of receiving an amputation compared with white patients (95% CI, 1.72-1.

129 ndow in early postnatal life wherein partial amputation culminates in a localized regeneration instea

130 Amputation data were obtained using Medicare institution

131 , chronic kidney disease (CKD), retinopathy, amputation, death or to the end of study.

132 0% (including some subjects who had required amputation) died within 1 year.

133 The amputation disparity also paradoxically increased for pa

134 ssion is rapidly depleted within 3 days post-amputation (dpa) but is highly upregulated by 7-14 dpa,

135 and QT intervals at 26 days post ventricular amputation (dpa).

136 w that adaptive patterns of limb usage after amputation drive cortical plasticity.

137 a major peripheral arterial disease-related amputation during the period between 2003 and 2010.

138 to compare the incidences of lower-extremity amputation, end-stage renal disease, acute myocardial in

139 therapy and all patients underwent curative amputation, except for 1 patient who developed metastase

140 Individuals with unilateral below-knee amputation expend more energy than non-amputees during w

141 High-speed videos and amputation experiments reveal that pectoral fins and the

142 I, that compensatory intact hand usage after amputation facilitates remapping of limb representations

143 nt surgery and from T2DM patients undergoing amputation for critical limb ischemia.

144 , new or worsening congestive heart failure, amputation for ischemic gangrene, or cardiovascular-rela

145 ted to the hospital in the year prior to the amputation for revascularization, wound-related care, or

146 s ago, and received bilateral below-the-knee amputations for ischemic ulcers of the lower limbs, pres

147 Cells at the site of amputation form a blastema and then proliferate and diff

148 ls and amputees over the first 12 weeks post-amputation found significant differences for the total a

149 The amputation-free survival benefit associated with an endo

150 The amputation-free survival benefit associated with an endo

151 uced the risk of amputation by 37%, improved amputation-free survival by 18%, and improved wound heal

152 undergoing endovascular repair had improved amputation-free survival compared with open repair at 30

153 undergoing endovascular repair had improved amputation-free survival compared with open repair at 30

154 r rates of mortality and MACCE and increased amputation-free survival in CLI patients.

155 cular and cerebrovascular events (MACCE) and amputation-free survival in critical limb ischemia (CLI)

156 ascular approach is associated with improved amputation-free survival over the long term with only a

157 ascular approach is associated with improved amputation-free survival over the long term with only a

158 , readmission, and reintervention costs, (2) amputation-free survival, (3) reintervention rate, and (

159 We evaluated amputation-free survival, overall survival, and relative

160 We evaluated amputation-free survival, overall survival, and relative

161 injury, prehospital shock, severity of limb amputation, head injury, and torso hemorrhage.

162 muscles in a patient who had undergone knee amputation improved control of a robotic leg prosthesis.

163 al artery disease and 10.61 [5.70-19.77] for amputation in eGFR <30 mL/min per 1.73 m(2) plus ACR >/=

164 Tail amputation in pigs appears to evoke acute and sustained

165 ration are independent risk factors for limb amputation in subjects with diabetes.

166 i and frequently requires radical surgery or amputation in the absence of appropriate treatment.

167 gi and frequently require radical surgery or amputation in the absence of appropriate treatment.

168 ed in M1 contralateral or ipsilateral to the amputation in three animals.

169 ly, we reported that, 6 weeks after forelimb amputation in young adult rats, new input from the shoul

170 About 85% of lower extremity amputations in diabetes are attributed to deep infection

171 ce- or procedure-related deaths and no major amputations in either group through 24-month follow-up.

172 betes resulting in >70,000 annual lower-limb amputations in the United States alone.

173 an cost of inpatient care in the year before amputation, including costs related to the amputation pr

174 In this study of 7 patients with lower limb amputations, inclusion of EMG signals and temporal gait

175 cted from the regeneration blastema after an amputation injury.

176 bypass surgery or angioplasty, limb or foot amputation, intermittent claudication with objective evi

177 directs nerves that lost their target in the amputation into redundant muscles in the region of the s

178 Arm-amputation involves two powerful drivers for brain plast

179 Restoration of touch after hand amputation is a desirable feature of ideal prostheses.

180 Digit tip regeneration following amputation is an innate response in some mammals, includ

181 Amputation is associated with decreased allograft and pa

182 Cortex plasticity after hand amputation is considered harmful, causing phantom limb p

183 ng superior long-term outcomes compared with amputation is unavailable.

184 Phantom pain after arm amputation is widely believed to arise from maladaptive

185 Some patients with lower leg amputations may be candidates for motorized prosthetic l

186 ing a novel in vivo murine hindlimb ischemia-amputation model.

187 mal muscle of patients undergoing lower limb amputation (n = 3), were analyzed for capillary-fiber ra

188 Following amputation, non-cluster zones became occupied with new i

189 Minor amputations not affecting the wound site were also repor

190 Amputation occurred in 17.6% presenting with ALI.

191 Less minor amputations occurred after DES until 6 months post-treat

192 When amputation occurs through a region containing ETs, a Dkk

193 ed trials with a relative risk (RR) on major amputation of 0.58 [95% confidence interval (CI), 0.40-0

194 surgical intervention and 12 (22%) underwent amputation of a lower extremity.

195 tal limbs; the latter may ultimately lead to amputation of a portion of the lower extremity.

196 Paralysis or amputation of an arm results in the loss of the ability

197 red a high-voltage electrical burn requiring amputation of his upper limbs.

198 re, fetuses had hemorrhages, syndactyly, and amputation of limbs, similar to human ABS.

199 djuvant doxorubicin or carboplatin following amputation of the affected limb.

200 veloped chronic rejection leading to partial amputation of the allograft.

201 Amputation of the dominant hand forces patients to use t

202 nic allograft vasculopathy eventually led to amputation of the graft.

203 ath, target lesion revascularization, or any amputation of the index limb at 30 days (+ 7 days) postp

204 lysis of cardiac regeneration after surgical amputation of the left ventricle (LV) (apical resection)

205 Selective amputation of the pharynx therefore permits the identifi

206 Amputation of the proximal region in mammals is not foll

207 ages (mpeg1(+)) in adult zebrafish following amputation of the tail fin, and detailed a migratory tim

208 increased, the rate of lung metastasis after amputation of the tumor-bearing limb.

209 ins significant regenerative potential after amputation of the ventricular apex.

210 Following amputation of the zebrafish ventricular apex, Notch rece

211 Subsequent amputations of the morphologically normal regenerates in

212 The influence of the degree of amputation on MNTs was also evaluated by comparing three

213 putation, patients are at heightened risk of amputation on the contralateral leg.

214 hen placing patients with symptomatic PVD or amputation on the wait-list.

215 cent cells does not increase upon repetitive amputation or ageing, in contrast to mammals.

216 later, phantom limbs-whether resulting from amputation or deafferentation-became illustrated, and so

217 (HR: 0.49, 95% CI: 0.24 to 0.97), and major amputation or death (HR: 0.53, 95% CI: 0.35 to 0.98).

218 d with a risk-adjusted 16% decreased risk of amputation or death compared with open over the study pe

219 d with a risk-adjusted 16% decreased risk of amputation or death compared with open over the study pe

220 protocol, and successful revascularization, amputation or death within 4 weeks occurred in only 8% a

221 wing severe craniofacial injuries, extremity amputations or massive tissue loss.

222 chiatric difficulties, the initial trauma of amputation, or adjusting to the transplantation process

223 events defined as acute limb ischemia, major amputation, or urgent peripheral revascularization for i

224 By demonstrating stable topography despite amputation, our finding questions the extent to which co

225 mild reductions in rates of lower extremity amputation over the past decade, few data exist on the u

226 Importantly, after a major amputation, patients are at heightened risk of amputatio

227 Following an amputation, patients had a considerable risk of all-caus

228 After amputation, planarians are capable of regenerating new a

229 e who received placebo but a greater risk of amputation, primarily at the level of the toe or metatar

230 e amputation, including costs related to the amputation procedure itself, was $22,405, but it varied

231 Amputations proximal to the Wnt-active nail progenitors

232 In patients with amputation, race did not have any impact.

233 The observed major amputation rate remained lower in the DES group until 2

234 there was a trend towards an increased major amputation rate through 12 months compared to PTA.

235 Amputation rate was improved more in trials wherein the

236 interval [CI]: 3.77 to 17.6; p < 0.001) and amputation rates (HR: 3.71; 95% CI: 1.33 to 10.3; p = 0.

237 nding was not associated with lower regional amputation rates (R = 0.10, P = .06).

238 high spending (R = 0.42, P = .002) and high amputation rates (R = 0.40, P = .004).

239 ificant disparities in revascularization and amputation rates according to race, socioeconomic status

240 ce for those with claudication and to reduce amputation rates among those with critical limb ischemia

241 tatin users compared with nonusers had lower amputation rates at 30 days (11.5% versus 14.4%; P<0.000

242 There were no differences in amputation rates between the 2 groups.

243 e common femoral artery did not reduce major amputation rates in patients with severe, nonrevasculari

244 Overall, the RCTs showed reduced amputation rates in the therapeutic arms of the included

245 reasing rates of in-hospital death and major amputation rates in the United States.

246 ie, major amputation at 6 months, with major amputation rates of 19% in the BMMNC versus 13% in the p

247 tween spending on vascular care and regional amputation rates remains unclear.

248 e considered, the beneficial effect on major amputation rates was considerably reduced and nonsignifi

249 ssociated with increased severity, increased amputation rates, and decreased revascularization rates

250 r regional spending is associated with lower amputation rates.

251 ions (thromboembolic venous/arterial events, amputations, recurrent/persistent thrombocytopenia, skin

252 limb allograft viability in a swine forelimb amputation/replantation model.

253 treatment of such patients, for many of whom amputation represents the only hope for alleviation of s

254 clear whether the below-knee lower extremity amputation risk extends across the class of medication,

255 ucleus (CN) 1 to 30 weeks following forelimb amputation showed that CN played an insignificant role i

256 generation and induces scar formation at the amputation site.

257 tro and in vivo following injection into the amputation site.

258 ecific complications (thromboembolic events, amputation, skin necrosis) occurred in 11.7% of patients

259 Amputation stimulates resident cells within a limited re

260 Amputation stimulates serotonin production in regenerati

261 er 10,000, respectively) but not in rates of amputation, stroke, or end-stage renal disease.

262 The mechanisms underlying poor amputation stump healing in the setting of diabetes are

263 N-acetylcysteine accelerates amputation stump healing in the setting of diabetes.

264 Amputation stump tissue perfusion and healing were evalu

265 rs the vascular milieu to improve healing of amputation stumps in diabetes using a novel in vivo muri

266 demonstrate that NAC accelerates healing of amputation stumps in the setting of diabetes and ischemi

267 -cluster zones over the first 12 weeks after amputation suggests that CN provides an unlikely substra

268 revascularization is effective in preventing amputation, the relationship between spending on vascula

269 However, we speculate that following amputation these latent shoulder inputs become expressed

270 unctional outcomes or in the rates of death, amputation, thrombosis, or reintervention.

271 3) leads to successful regeneration, whereas amputation through a more proximal location, e.g. the su

272 of the adult mouse digit is level dependent: amputation through the distal half of the terminal phala

273 A safety signal driven by major amputations through 12 months was observed in the IA-DEB

274 By contrast, upon amputation, tph1b(+) joint cells give rise to fibroblast

275 the past centuries of scientists performing amputations, transplantations and molecular experiments,

276 n RNAi screen of 356 genes upregulated after amputation, using successful feeding as a proxy for rege

277 nces similar to world-class athletes without amputations, using a carbon fibre running-specific prost

278 3+/-0.13 months in African Americans without amputation versus 54.9+/-1.06 months in African American

279 0.67 months in non-African Americans without amputation versus 55.7+/-0.65 months in non-African Amer

280 -cause mortality was higher in patients with amputation versus those without amputation (19.9% vs. 7.

281 normal levels while subjects with simulated amputation walked on a treadmill at 1.25 m . s(-1).

282 The subsequent amputation was confirmatory.

283 The level of amputation was distal in all cases except for 2 patients

284 The prevalence of amputation was higher in those with PVD versus those wit

285 No major amputation was needed.

286 Although blood loss after tail tip amputation was similar in HRG-deficient and wild-type mi

287 Amputation was used as a treatment in field hospitals to

288 genitors in intact planarians, and following amputation we observed an enrichment of coe(+) and sim(+

289 rdings encompassing the first 4-5 days after amputation, we capture the cellular events that contribu

290 ent skill is related with the bilateral hand amputation, we studied the primary motor cortex by using

291 In-hospital mortality and amputation were coprimary outcomes.

292 ent associations between patient factors and amputation were examined using multivariable Cox regress

293 ation for peripheral arterial disease before amputation were low, and testing varied by patient, prov

294 in exposure in the database, the majority of amputations were observed on canagliflozin.

295 ; hazard ratio, 1.97; 95% CI, 1.41 to 2.75); amputations were primarily at the level of the toe or me

296 Lower extremity amputations were similarly increased in the secondary an

297 CI, -68.0 to -60.9), followed by stroke and amputations, which each declined by approximately half (

298 with a substantial improvement prediction of amputation with ACR (difference in c-statistic 0.058, 95

299 rafted into a regeneration-incompetent digit amputation wound resulted in a locally enhanced populati

300 re may be potential to avoid approximately 1 amputation/year for every 2 patients successfully treate